Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

Opdualag

Drug and asset intelligence for Opdualag with 4 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
2
Catalysts
2
Stage
Development stage unavailable

Sponsor company

Bristol Myers Squibb →

Mechanism of action

Combination Therapy

Recent signals(2)

ClinicalJuly 2, 2026

Study on Hepzato Kit and Opdualag for Metastatic Melanoma Initiated

A clinical trial is underway to evaluate the safety and efficacy of Hepzato Kit combined with Opdualag in metastatic melanoma patients with liver metastasis.

RegulatoryJune 21, 2026

FDA Accepts Supplemental Application for OPDUALAG by Bristol Myers Squibb

The FDA has accepted a supplemental application for OPDUALAG, a combination of nivolumab and relatlimab-rmbw.

Upcoming milestones

No catalysts indexed for this entity yet.

Related catalysts(2)

Topline Data

— Opdualag

July 2, 2026 · N/A

Topline Data

Bristol Myers Squibb — OPDUALAG

June 21, 2026 · N/A

Indications

No related entities indexed yet.

Therapeutic areas

Combination Therapy →
Oncology →
Oncology · Combination Therapy →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.